For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Merck MK7339-001/GOG-3036

Trial Overview

Official Title

First-Line Chemotherapy Plus Pembrolizumab and Olaparib for BRCA Non-Mutated Advanced Epithelial Ovarian Cancer (EOC)

Study Purpose

To test the safety of the study drug, pembrolizumab (MK- 3475) with chemotherapy followed by olaparib OR pembrolizumab with chemotherapy compared to chemotherapy alone to see how well the drugs work and to see how your body handles them.

Diagnosis

Untreated Non-Mutated BRCA Advanced Epithelial Ovarian Cancer (EOC), fallopian tube cancer or primary peritoneal cancer.

Eligibility

First line, BRCA non-muted, treatment naïve, Stage III or IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

  • Group 1 - Carboplatin/paclitaxel for 5 cycles plus pembrolizumab 200 mg every 3 weeks for up to 35 infusions and olaparib 300 mg (twice daily).
  • Group 2 - Carboplatin/paclitaxel for 5 cycles plus pembrolizumab 200 mg every 3 weeks for up to 35 infusions and olaparib placebo.
  • Group 3 - Carboplatin/paclitaxel for 5 cycles plus pembrolizumab placebo  every 3 weeks for up to 35 infusions and olaparib placebo.

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Female
Age
19 years and older
Phase
Phase III
Methodist Health System Trial Code
MK7339-001/GOG-3036